BIOATLA INC. - COMMON

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

07 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

31 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

04 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

23 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

08 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

01 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

25 Jul 2024 16:39:55 By Nasdaq GlobeNewswire

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

23 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

27 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the Jefferies Global Healthcare Conference

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 16:05:00 By Nasdaq GlobeNewswire

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

14 May 2024 15:05:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the Citizens JMP Life Sciences Conference

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

07 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 15:35:00 By Nasdaq GlobeNewswire